Alpha Crest Capital Management LLC Intra Cellular Therapies, Inc. Transaction History

Alpha Crest Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $224,303 - $315,127	-5,253 Reduced 51.32%	4,982 $232,000
Q2 2022 Aug 11, 2022	BUY	$43.0 - $65.64 $440,105 - $671,825	10,235 New	10,235 $584,000
Q1 2022 May 12, 2022	SELL	$38.74 - $62.09 $178,204 - $285,614	-4,600 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$35.2 - $53.42 $161,920 - $245,732	4,600 New	4,600 $241,000
Q3 2021 Nov 10, 2021	SELL	$28.72 - $42.49 $149,344 - $220,948	-5,200 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$29.3 - $44.5 $152,360 - $231,400	5,200 New	5,200 $212,000
Q1 2021 May 13, 2021	SELL	$30.8 - $39.51 $255,640 - $327,933	-8,300 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$23.34 - $32.22 $193,722 - $267,426	8,300 New	8,300 $264,000

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.85B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.